Biotechnology company Infex Therapeutics has raised £4.3 million to support the development of anti-infective therapies targeting antimicrobial-resistant infections.
The funding round was led by Jon Moulton, with participation from the GM&C Life Sciences Fund, managed by Catapult Ventures, alongside existing high-net-worth investors. Headquartered in Macclesfield, Cheshire, the company is focused on developing novel treatments for severe infectious diseases caused by highly resistant pathogens.
What The Company Does
Infex Therapeutics develops anti-infective drug candidates aimed at addressing antimicrobial resistance (AMR), one of the most significant global public health challenges facing healthcare systems today.
The company focuses on identifying, acquiring, and advancing early-stage therapeutic assets targeting difficult-to-treat bacterial infections. Its strategy centres on progressing first-in-class therapies toward clinical proof of concept for pathogens where current antibiotic options are becoming less effective.
Among its lead programmes is RESP-X, a treatment candidate targeting Pseudomonas aeruginosa in respiratory infections. The company has already completed a Phase IIa clinical study for the programme.
Infex is also developing its MET-X initiative, which focuses on resistance-bypass therapies designed to overcome bacterial defence mechanisms against existing antibiotics. In parallel, the company is advancing preclinical work on BamA inhibitors targeting highly resistant Gram-negative bacteria.
The company has additionally established a clinical development partnership with Venus Remedies in India for the MET-X programme.
Advertisement
Market Context / Industry Background
Antimicrobial resistance is increasingly recognised as a major global healthcare threat as bacterial pathogens continue to evolve resistance to existing antibiotics. Health authorities and researchers have warned that drug-resistant infections could significantly increase mortality rates and healthcare costs if new treatment options are not developed.
Despite the growing urgency, antibiotic development has historically attracted less commercial investment than other therapeutic categories due to lengthy development timelines, scientific complexity, and limited economic incentives.
This has contributed to renewed public and private investment into biotechnology companies developing novel anti-infective therapies, particularly those focused on resistant Gram-negative pathogens, which are considered among the most difficult bacterial infections to treat.
Governments and healthcare organisations across Europe and globally are also increasing support for antimicrobial innovation through partnerships, funding programmes, and regulatory initiatives designed to strengthen the anti-infective pipeline.
Founder / Investor Commentary
CEO Dr Peter Jackson described the funding as validation of the company’s progress in developing new therapies to address antimicrobial resistance.
According to Jackson, the investment will support advancement of RESP-X toward later-stage clinical development while also expanding the MET-X programme and strengthening the company’s broader pipeline targeting resistant pathogens.
The participation of both institutional and private investors reflects continued interest in biotechnology platforms addressing unmet needs within infectious disease treatment and global public health infrastructure.
Growth Plans / Use Of Funds
The newly raised funding will be used to advance multiple programmes within Infex Therapeutics’ pipeline.
This includes continued clinical development of RESP-X following its Phase IIa trial, expansion of the MET-X resistance-bypass initiative, and progression of preclinical research into BamA inhibitor therapies.
The company also plans to continue strengthening international clinical development partnerships and advancing additional anti-infective candidates toward global clinical trials.
About Infex Therapeutics
Infex Therapeutics is a UK biotechnology company founded in 2016 and headquartered at Alderley Park in North West England. The company develops therapies targeting severe infectious diseases and antimicrobial-resistant pathogens through the acquisition and advancement of early-stage drug candidates. Infex Therapeutics focuses on progressing novel anti-infective therapies toward clinical development to address unmet needs in global infectious disease treatment.
